Electrocore LLC
$ 10.25
0.69%
12 Jun - close price
- Market Cap 85,031,000 USD
- Current Price $ 10.25
- High / Low $ 10.45 / 9.80
- Stock P/E N/A
- Book Value -0.70
- EPS -1.77
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.58 %
- ROE -4.79 %
- 52 Week High 10.45
- 52 Week Low 4.16
About
electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.
Analyst Target Price
$19.17
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-19 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-03-12 | 2024-11-13 | 2024-08-07 | 2024-05-08 | 2024-03-13 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.59 | -0.34 | -0.4 | -0.44 | -0.47 | -0.4 | -0.31 | -0.38 | -0.53 | -0.61 | -0.68 | -1.02 |
| Estimated EPS | -0.61 | -0.3925 | -0.4 | -0.32 | -0.45 | -0.3 | -0.33 | -0.43 | -0.59 | -0.61 | -0.79 | -0.93 |
| Surprise | 0.02 | 0.0525 | 0 | -0.12 | -0.02 | -0.1 | 0.02 | 0.05 | 0.06 | 0 | 0.11 | -0.09 |
| Surprise Percentage | 3.2787% | 13.3758% | 0% | -37.5% | -4.4444% | -33.3333% | 6.0606% | 11.6279% | 10.1695% | 0% | 13.9241% | -9.6774% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ECOR
2026-06-13 03:05:20
An insider at ElectroCore, Daniel S. Goldberger, reported a direct sale of 80,000 shares of common stock for a total of $544,000. These shares were sold in multiple transactions between April 23, 2026, and May 26, 2026, at prices ranging from $6.00 to $8.52, with a weighted average price of $6.80. Following these transactions, Goldberger directly owns 211,471 shares of the company's common stock.
2026-06-12 23:10:20
This page provides an overview of insider trading activity for electroCore, Inc. (ECOR), along with institutional ownership and other financial data. It also details the company's patent grants, corporate lobbying, and analyst ratings, presenting a comprehensive profile for investors. The platform offers tools like backtesters and alerts, and financial metrics are provided with disclaimers regarding historical performance.
2026-06-12 23:10:20
Daniel S. Goldberger, a former officer and director of electroCore, Inc. (NASDAQ:ECOR), recently sold 80,000 shares for $544,000, averaging $6.80 per share. This transaction occurred between April 23, 2026, and May 26, 2026, with the stock currently trading significantly higher at $10.25. The company also reported record Q1 2026 revenue of $9.6 million, a 43% increase, despite a GAAP net loss of $5.3 million, and is involved in a clinical study for fibromyalgia treatment.
2026-06-12 22:10:20
A former officer and director of electroCore, Daniel S. Goldberger, sold 80,000 shares of common stock at a weighted average price of $6.80 per share through open-market transactions between April 23, 2026, and May 26, 2026. Following these sales, Goldberger still holds 211,471 shares of electroCore common stock. The transactions were made subject to Rule 144, and the filing indicates a negative sentiment for the company due to the insider sale.
2026-06-09 14:10:28
electroCore, Inc. announced that a review article titled "Without getting under your skin: non-invasive stimulation activates the vagus nerve" has been accepted for publication in Frontiers in Neuroscience. The article synthesizes extensive scientific evidence, including anatomical, computational, and clinical trial data, to support that cervical non-invasive vagus nerve stimulation (nVNS) can effectively activate vagal pathways without surgical implantation. This publication reinforces cervical nVNS as a clinically validated approach in bioelectronic medicine.
2026-06-09 11:40:36
electroCore, Inc. announced that its review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for publication in Frontiers in Neuroscience. The article synthesizes scientific evidence demonstrating that cervical non-invasive vagus nerve stimulation (nVNS) can activate vagal pathways without surgical implantation, addressing previous skepticism. This supports cervical nVNS as a clinically validated approach in bioelectronic medicine.
